In this episode, Benjamin dives into the story of how Exeliom Biosciences forged its path, without a traditional roadmap, to become a clinical-stage biotech with 5 ongoing clinical studies in 3 therapeutic areas
The drug semaglutide a GLP-1 receptor agonist research peptide widely studied in metabolic and incretin-pathway research
- Muscle Growth & Endurance: Facilitates muscle growth and boosts endurance levels
Oral B12 has only about 1 to 2 percent absorption, while injections are absorbed at 55 to 97 percent
A recent small, breakthrough study published in the journal Aging found using a comprehensive, personalized approach, including diet and exercise, actually reversed symptoms of Alzheimers disease
Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice